Overview Treatment of Patients With Anxiety Disorder (0777-022) Status: Completed Trial end date: 2003-02-01 Target enrollment: Participant gender: Summary The purpose of the study is to examine the safety and efficacy of MK0777 during treatment for Generalized Anxiety Disorder. Phase: Phase 2 Details Lead Sponsor: Merck Sharp & Dohme Corp.